Pfizer and Merck reported compelling survival benefits from combining Pfizer's antibody-drug conjugate Padcev with Merck’s Keytruda in patients with muscle-invasive bladder cancer deemed ineligible for chemotherapy. The perioperative regimen demonstrated clinically meaningful improvements compared to surgery alone, potentially expanding Padcev's indications into neoadjuvant and adjuvant settings. These results add to Pfizer's growing oncology franchise amid the need to offset COVID-19-related revenue declines.